The subgroups were defined by baseline characteristics that are known to be potential modifiers of risk to conversion to clinically-definite multiple sclerosis, including age, gender, first classification of demyelinating event, presence of T1 Gd+ lesions, and number of active T2 lesions.
The director of the Jefferson Headache Center at Jefferson University Hospital discussed the need for physicians to revisit how they treat patients with chronic migraine who have developed medication overuse headache.
The Director of the Multiple Sclerosis and Hereditary Neuropathy Centers at Seton Hall-Hackensack Meridian School of Medicine shared insight into what clinicians should know about Charcot-Marie-Tooth disease.
The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.
Despite a 40-fold increase in the use of LAAC in a 9-year period, those who had a history of stroke with major bleeds and higher comorbidity were less likely to have LAAC.
Similar rates of successful clinical and procedural EVT outcomes were reported in patients with and without prestroke disability; however, prospective studies are needed to confirm this finding.
The research fellow in the Department of Radiology at Mayo Clinic Jacksonville spoke about the reasoning for conducting this study and what the findings mean for physicians in clinical practice.
The director of the Pediatric Stroke Program at CHOP discussed the findings of a single-center study exploring the incidence of children presenting with acute arterial ischemic stroke who may have been eligible for mechanical thrombectomy.
The associate professor of neurology at Mayo Clinic spoke about the findings of a population-based cohort study seeking to investigate the incidence of levodopa-induced dyskinesia in atypical parkinsonism.
The director of the Pediatric Stroke Program at CHOP spoke about the need to improve early recognition and assessments in pediatric stroke, and how ultimately, awareness of the condition is a huge step toward achieving this goal.
NfL levels were reduced during treatment with fingolimod, providing further evidence of the long-term benefit of the drug and demonstrating a greater impact of highly effective therapy in relapsing-remitting multiple sclerosis.
The staff neurologist at Cleveland Clinic shared his insight from the study, as well as what these data can do to further inform the use of this biomarker in progressive MS trials.
The lead investigator noted that “the study results are a promising step toward having a scientifically-validated tool for clinical use that can facilitate physician-patient conversations and ultimately help to get ahead of MS progression.”
The International Project Team Lead spoke about the results of study endpoints that assessed the potential for next-morning residual effects of lemborexant, which is in development for insomnia.
Evobrutinib is the first BTK inhibitor to demonstrate clinical proof of concept in multiple sclerosis, reducing Gd+ lesions in a 75-mg, once-daily dose.
Suvorexant improved the mean total sleep time by 28.2 minutes for the patients receiving the treatment versus placebo, equating to a mean increase of 73.4 minutes with the orexin receptor antagonist.
The chief medical officer of Neurocrine Biosciences spoke about how long-term data on valbenazine (Ingrezza) has helped shape the understanding of the effect tardive dyskinesia can have on patients, and how it can inform better utilization of the medication.
The assistant professor of neurology at Mount Sinai Health System spoke about the recent trend toward approaching migraine in a more holistic fashion, and the incorporation of nonpharmacologic options for patients with the chronic headache condition.
Patients across all dosing groups saw statistically significant and clinically relevant reductions in migraine days during the 12-week treatment period compared with the placebo group.
Enough evidence to support further evaluation in a phase 3 trial in myasthenia gravis has been collected from these new phase 2 data of zilucoplan, formerly known as RA101495 SC.
The director of Translational Research and Epilepsy Clinical Trials at NYU Langone spoke about the nuance involved in diagnosing epilepsy and the misconceptions about how seizures present in the majority of patients.
Compared to interferon beta-1a, the reduction of grey matter volume loss was greater in those treated with both doses of the oral S1P receptor modulator across all age groups, including the youngest patients at the highest risk for brain volume loss.
The director of Child and Adolescent Psychiatry at Mount Sinai Health System spoke about the results of the phase 2 study of OV101 (gaboxadol), and the next steps for the phase 3 trial.
The investigators observed a dose-dependent reduction of mutant huntingtin concentration in the cerebrospinal fluid of patients who received HTTRX, supporting the launch of a confirmatory phase 3 trial.
The professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.
Although the primary end point of centrally video-rated TETRAS Performance Subscale did not achieve statistical significance, CX-8998-treated patients showed significant improvements in a number of other measurements.
The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about the Visual Analog Scale that the company developed to help better understand the impact that potential treatments have on patients with Fragile X syndrome.
The anti-CGRP drug, which was recently approved for the prevention of migraine in adults, showed significant reductions in weekly cluster headache attack frequency by week 3 in 76% of patients.
A 75 mg orally dissolving tablet formulation of the calcitonin gene-related peptide receptor antagonist met both co-primary end points of freedom from the patient-indicated most bothersome symptom and freedom from pain at 2 hours.
The sphingosine1-phosphate receptor modulator was shown to annualize relapse rates by more than 70% for patients switching from other disease-modifying therapies such as dimethyl fumarate; teriflunomide, and daclizumab.
